Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma - European Journal of Nuclear Medicine and Molecular Imaging Purpose High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas...

1/3 Excited to share two recent publications! 🧠💡 First, we explored radioligand target expression in high-grade #meningioma, finding #SSTR2a and #FAP variably expressed, with implications for patient selection and radioligand therapy design. @nathaliealbert.bsky.social doi.org/n786

Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma

🥁🥁New article in EJNMMI: Expression of #SSTR2a, #FAP, #HER2 and #HER3 as potential radionuclide therapy targets in higher-grade #meningioma.
rdcu.be/eaSo6
@mj-mair.bsky.social @nathaliealbert.bsky.social @eanm.org